|
|
|
|
|
|
|
|
|
|
|
05.08.25 - 13:48
|
"Difficult Quarter": HIMS Plunges On Weak GLP-1 Sales (ZeroHedge)
|
|
|
"Difficult Quarter": HIMS Plunges On Weak GLP-1 Sales
Hims & Hers Health (HIMS), the telehealth platform known for selling compounded GLP-1 weight-loss drugs, tumbled in premarket trading in New York after missing Wall Street's revenue estimates in its Monday after-hours earnings release, despite posting a profit beat.
Despite strong year-over-year growth in revenue (+73%) and beating EPS and EBITDA estimates, HIMS fell short of revenue and subscriber projections in the second quarter, raising concerns about sustaining momentum, especially with GLP-1s accounting for about 35% of revenue and regulatory scrutiny around GLP-1 compounds mounting.
HIMS Q2 Earnings Summary:
Revenue: $544.8M (+73% YoY) — missed estimate of $552.1M
GLP-1 revenue: ~$190M
EPS: $0.17 — beat estimate of $0.15 (vs. $0.06 YoY)
Adj. EBITDA: $82.2M — beat estimate of $72M (vs. $39.3M YoY)
Gross Margin: 76% — beat estimate of 75.6% (but down from 81% YoY)
Subscribers: 2.44M (+31% YoY) — mis...
|
|
|
|
|
|
|
|
|
04.08.25 - 21:54
|
Live: Will Hims & Hers (HIMS) Rally After Q2 Earnings After the Bell? (24/7 Wall St.)
|
|
|
Live Updates Live Coverage Updates appear automatically as they are published. How HIMS Performed After Recent Earnings 3:00 pm HIMS has delivered four consecutive post-earnings rallies, averaging +20.8% over 7 days — one of the most consistent momentum profiles in small-cap health tech. Quarter Earnings Date 1-Day Move 7-Day Move 14-Day Move Q1 2025 May […]
The post Live: Will Hims & Hers (HIMS) Rally After Q2 Earnings After the Bell? appeared first on 24/7 Wall St.....
|
|
|
|
|
|
|
|
|
06.05.25 - 08:39
|
Hims & Hers mit Top-Zahlen nach Novo-Nordisk-Deal – Aktie fällt (Der Aktionaer)
|
|
|
Am Montag nach US-Börsenschluss hat das US-Unternehmen Hims & Hers die Zahlen für das erste Quartal vorgelegt und durch die Bank überzeugt. Dennoch verliert die Aktie im nachbörslichen Handel wieder an Boden. Im Vorfeld war das Papier durch das Bekanntwerden einer Zusammenarbeit mit Novo Nordisk bereits kräftig angesprungen....
|
|
|
06.05.25 - 00:36
|
Hims & Hers (HIMS) Blows Out Earnings Expectations (24/7 Wall St.)
|
|
|
Hims & Hers Health (NYSE:HIMS) reported a strong financial performance for Q1 2025, with revenue reaching $586 million, marking a 111% increase year-over-year. The company achieved a net income of $49.5 million, significantly up from $26.0 million in the previous quarter, and an Adjusted EBITDA of $91.1 million. Subscriber growth was robust, with a 38% […]
The post Hims & Hers (HIMS) Blows Out Earnings Expectations appeared first on 24/7 Wall St.....
|
|
|
|
|
|
|
|
|
05.05.25 - 16:48
|
Hims & Hers (NYSE: HIMS) Live: Complete Earnings Coverage (24/7 Wall St.)
|
|
|
Live Updates Live Coverage Updates appear automatically as they are published. Watching for GLP-1 Fallout 10:14 am by Joel South The telehealth platform was hit earlier this year by the Food & Drug Administration declaring there was no longer a shortage of Ozempic or Wegovy, the GLP-1 drugs sold by Novo Nordisk (NYSE:NVO) for the […]
The post Hims & Hers (NYSE: HIMS) Live: Complete Earnings Coverage appeared first on 24/7 Wall St.....
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
